United States

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

4:00pm EDT
Change (% chg)

$0.16 (+1.41%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for SCMP.OQ


Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through... (more)


Beta: 1.39
Market Cap(Mil.): $520.62
Shares Outstanding(Mil.): 45.79
Dividend: --
Yield (%): --


  SCMP.OQ Industry Sector
P/E (TTM): 23.01 41.28 37.71
EPS (TTM): 0.49 -- --
ROI: 9.07 -9.20 14.43
ROE: 23.51 -9.24 15.61

BRIEF-Sucampo Pharmaceuticals updates on Cobiprostone Development Program

* Sucampo provides update on Cobiprostone Development Program Source text for Eikon: Further company coverage:

Jul 11 2016

BRIEF-Sucampo reports Q1 adjusted earnings per share $0.21

* Q1 earnings per share view $0.19 -- Thomson Reuters I/B/E/S

May 04 2016

BRIEF-Sucampo says to discontinue development of Cobiprostone for PPI-Refractory NERD/SGERD

* Sucampo reports top-line data from phase 2a study of cobiprostone in patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (SGERD)

Apr 19 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.